DiaSorin (OTCMKTS:DSRLF) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research cut shares of DiaSorin (OTCMKTS:DSRLF) from a hold rating to a strong sell rating in a report published on Thursday morning,Zacks.com reports.

A number of other equities research analysts have also commented on the company. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of DiaSorin in a research report on Tuesday. Piper Sandler began coverage on shares of DiaSorin in a report on Thursday, June 11th. They set a “neutral” rating on the stock. UBS Group lowered shares of DiaSorin from a “buy” rating to a “neutral” rating in a research note on Thursday, April 9th. Finally, BNP Paribas Exane downgraded shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research report on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce”.

DiaSorin Stock Performance

DSRLF opened at $85.56 on Thursday. DiaSorin has a 12 month low of $66.50 and a 12 month high of $100.00. The company has a fifty day simple moving average of $79.59 and a 200 day simple moving average of $76.58.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.